Head and neck cancer, including oral squamous cell carcinoma (OSCC), is the sixth leading malignancy worldwide. OSCC is an aggressive tumor and its prognosis has exhibited little improvement in the last three decades. Comprehensive elucidation of OSCC’s molecular mechanism is imperative for early detection and treatment, improving patient survival. Based on broadly accepted notions, OSCC arises from multiple genetic alterations caused by chronic exposure to carcinogens. In 2011, research revealed 10 key alterations fundamental to cancer cell development: sustaining proliferative signaling, evading growth suppressors, avoiding immune destruction, activating invasion and metastasis, tumor-promoting inflammation, enabling replicative immortality, inducing angiogenesis, genome instability and mutation, resisting cell death, and deregulating energetics. This review describes molecular pathological findings on conventional and novel hallmarks of OSCC prognostic factors. In addition, the review summarizes the functions and roles of several molecules as novel OSCC prognosticators.
Background:MicroRNA (miRNA)-126 (miR-126) is an endothelial-specific miRNA located within intron 7 of epidermal growth factor-like domain 7 (EGFL7). However, the role of miR-126 in cancer is controversial.Methods:We examined the function of miR-126 in oral squamous cell carcinoma (OSCC) cells. Furthermore, a series of 118 cases with OSCC were evaluated for the expression levels of miR-126.Results:MicroRNA-126 (miR-126) was associated with cell growth and regulation of vascular endothelial growth factor-A activity, and demethylation treatment increased expression levels of miR-126 and EGFL7 in OSCC cells. A significant association was found between miR-126 expression and tumour progression, nodal metastasis, vessel density, or poor prognosis in OSCC cases. In the multivariate analysis, decreased miR-126 expression was strongly correlated with disease-free survival.Conclusion:The present results suggest that miR-126 might be a useful diagnostic and therapeutic target in OSCC.
Melanoma inhibitory activity (MIA) is an 11-kDa secretory protein isolated from malignant melanoma cells that is correlated with invasion and metastasis in various human malignancies. We examined MIA expression in 62 oral squamous cell carcinomas (OSCC) by immunohistochemistry. MIA expression was significantly associated with nodal metastasis (P = 0.00018). MIA expression was also associated with expression of high mobility group box-1 (HMGB1) (P < 0.0001) and lymph vessel density (P < 0.0001). Expression levels of MIA, HMGB1, nuclear factor kB (NFkB) p65 and HMGB1-NFkB p65 binding were significantly higher in a metastatic human OSCC cell line (HSC3) than those in a non-metastatic OSCC cell line (HSC4). H ead and neck cancer is the sixth most common malignancy worldwide and the first leading cause of cancer death in South Asia.(1) About 300 000 patients develop OSCC every year in the world.(2,3) OSCC has a high potential for nodal metastasis and locoregional invasion, (4) from which over 50% of patients die.(5,6) To control lymph-node metastasis of OSCC, we need to study the molecular aspects of the mechanism of metastasis.MIA is an 11-kDa secretory protein isolated from supernatants of HTZ-19 malignant melanoma cells, (7,8) the gene locus of which is mapped to chromosome 19q13.32-13.33.(9) Although previous reports indicated that MIA is correlated with invasion and metastasis in malignant melanoma, (10)(11)(12) breast cancer,chondrosarcoma, (13) glioma, (14) and pancreatic cancer,the definite functions of MIA for cancer cells are still unclear.HMGB1 has a dual role as an extracellular secretory protein and a chromosomal structural protein.(16) HMGB1 works as a cytokine or a growth factor in neural ontogenesis, septic inflammation and neoplasm. HMGB1 is also considered an amphoterin, which is isolated as a motility factor in neurite outgrowth.(17) We previously reported coexpression of HMGB1 and receptor for advanced glycation end products (RAGE), which is a major membrane receptor for HMGB1 and is significantly associated with tumor progression and metastasis (18)(19)(20)(21)(22)(23)(24) and suppression of tumor-associated macrophages. (25,26) As a chromatin structural protein, HMGB1 participates in gene expression, DNA repair and functions of the p53 family.(27) Recently, HMGB1 was revealed to interact with NFkB p65 to accelerate MIA expression. (28,29) HMGB1 and NFkB p65 concurrently bind to a 30-bp region in the promoter region of the MIA gene designated as the highly conserved region (HCR).MIA is suspected to play an important role as a pro-metastatic factor in HMGB1-overexpressing cancers. In the present study, we analyzed the relationship between MIA expression and nodal metastasis and HMGB1 expression in human OSCC. Materials and MethodsTumor specimens. Sixty-two formalin-fixed, paraffin-embedded specimens of primary OSCC were randomly selected at Nara Medical University Hospital, Kashihara, Japan. None of the samples was treated using neo-adjuvant therapy. Medical records and prognostic follow-up data w...
Heme oxygenase (HO)-1 is a key player reducing cytotoxicity and enhancing protumoral effects of nitric oxide (NO). We examined zinc protoporphyrin (ZnPP) IX, an HO-1 inhibitor, to affect tumor growth of LL/2 mouse lung cancer cells. ZnPPIX reduced HO-1 expression and HO activity in LL/2 cells, whereas cobalt PPIX (CoPPIX), an HO-1 activator, increased both. LL/2 cells treated with sodium nitropurusside, an NO donor, showed growth inhibition dose-dependently, which was enhanced by ZnPPIX cotreatment, but was reduced by CoPPIX. In mice tumors, ZnPPIX decreased HO-1 expression. LL/2-tumors were found in 88% (7/8) vehicle-treated mice, whereas tumors were found in 38% (3/8) and 25% (2/8) mice treated with 5 and 20 lg/mouse ZnPPIX, respectively (p 5 0.0302). Tumor growth was inhibited dose-dependently by ZnPPIX. Vascular endothealial growth factor concentration in tumors was reduced by ZnPPIX (p 5 0.0341). Microvessel density (MVD) in ZnPPIX-treated tumors was lower than that in vehicle-treated tumors (p 5 0.0362). Apoptotic cell count in ZnPPIX-treated tumors was higher than that in vehicletreated tumors (p 5 0.0003). In contrast, CoPPIX treatment increased HO-1 expression, enhanced tumorigenicity and MVD and reduced apoptosis. From these findings, inhibition of HO-1 by ZnPPIX provides relevant antitumoral effects. ' 2006 Wiley-Liss, Inc.Key words: nitric oxide; heme oxygenase-1; zinc protoporphyrin IX Nitric oxide (NO) possesses various biological activities in physiological and pathological processes. 1 Reduction in muscle tonus by NO, which is produced by endothelial NO syntheses (eNOS) in vascular smooth muscle, endothelial cells or endothelial pericytes induces vasodilation and increase in blood supply. 1-4 NO-induced cell viability and angiogenesis are essential in regeneration of the liver, renal and heart. 5-8 NO produced by nerve NOS is an active neurotransmitter in intestinal nerve plexus. 9,10 Vasodilation, angiogenesis and antiapoptotic effect of NO play pivotal roles in tumor progression and metastasis. 1,11,12 In tumors, NO is produced by inducible NOS (iNOS) in tumor cells and inflammatory cells. 4,13 NO has bioactive effects to cells. However, NO also possesses a cytotoxic effect. 14-16 NO induces apoptosis in tumor cells at high concentrations. 14,16 High concentration of NO produced by iNOS is a main source of antitumoral capacities of mouse macrophages. 4,13,17 When tumor cells are exposed to both effects of NO, protumoral and antitumoral effects, the tumor cells escape from antitumoral effect of NO by heme oxygenease-1 (HO-1). 15 HO-1 increases resistance to NO of tumor cells by upregulation of Bcl-2. 14,16,18 We demonstrated that repression of HO-1 by antisense oligonucleotides in human cancer cell lines enhanced cytotoxicity of NO supplied by sodium nitroprusside (SNP). 14 The aforementioned findings suggest that HO-1 is a target of NO-induced antitumoral treatment.HO-1 is an enzyme catalyzing the convertizing reaction of heme to carbone monoxide, ion and biliverdine. HO-1 is also known as an ...
High mobility group (HMGB)1/amphoterin is a multifunctional cytokine involved in invasion and metastasis of cancer and in inflammation. To investigate HMGB1/amphoterin effects on macrophages, U937 human monocytic leukemia cells and rat peritoneal and human alveolar macrophages were examined. U937 cells expressed low levels of an HMGB1/amphoterin receptor, receptor for advanced glycation end-products (RAGE), whereas RAGE production was induced in differentiated phorbol 12-myristate 13-acetate (PMA)-U937 cells. Treatment with cultured medium of HMGB1/amphoterin-secreting WiDr human colon cancer cells showed growth inhibition of both U937 and PMA-U937 cells and apoptosis in PMA-U937 cells. The number of PMA-U937 cells was markedly decreased by co-culture with WiDr cells exposed to HMGB1/amphoterin sense S-oligodeoxynucleotide (ODN) in spheroids or monolayers. In contrast, PMA-U937 cells co-cultured with WiDr cells exposed to HMGB1/amphoterin anti-sense S-ODN were preserved in number. PMA-U937 cells exposed to RAGE anti-sense S-ODN were insensitive to WiDr-cultured medium. Recombinant human HMGB1/amphoterin induced growth inhibition in thioglycollate-induced rat peritoneal macrophages, PMA-U937 cells, and human alveolar macrophages, an effect that was abrogated by absorption with anti-HMGB1 antibody. Phosphorylation of JNK and Rac1 was induced in PMA-U937 cells treated with HMGB1/amphoterin. These results suggest that HMGB1/amphoterin induces growth inhibition and apoptosis in macrophages through RAGE intracellular signaling pathway.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.